Transcept's TO-2061 misses in OCD Phase II

Transcept Pharmaceuticals Inc. (NASDAQ:TSPT) said twice-daily oral TO-2061 as adjunctive therapy missed the primary endpoint vs. placebo in a Phase II trial to treat treatment-resistant obsessive comp...